|

Imaging Study in Metastatic Clear Cell RCC.

RECRUITINGEarly 1Sponsored by RayzeBio, Inc.
Actively Recruiting
PhaseEarly 1
SponsorRayzeBio, Inc.
Started2026-06-15
Est. completion2027-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in Subjects with Metastatic Clear Cell Renal Cell Cancer (RCC).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* At least 18 years old at the time of signing the informed consent form (ICF).
* Biopsy proven metastatic clear cell renal cell carcinoma (RCC)

Exclusion Criteria:

* Subjects taking below mentioned medications that cannot be stopped 5 half-lives prior to RYZ512 administration and cannot be restarted until all study-related imaging is completed: Anticonvulsants, Antipsychotics, Carbonic Anhydrase inhibitors, COX-2 Inhibitors, Sulfatase Inhibitors, Sulfonamides
* Women of Childbearing Potential that are pregnant or breastfeeding.

Note: Additional criteria may apply and will be assessed by the study site

Conditions2

CancerMetastatic Clear Cell Renal Cell Carcinoma

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.